Novo Nordisk's Buyback Tops DKK 12 Billion as Child Obesity Trial Delivers and US Price Cuts Loom
Published on 11/17/2026 at 07:40 | Editorial boerse-global.deNovo Nordisk has now repurchased 43,734,179 of its B-shares since the programme began on 4 February, spending DKK 12,118,073,269 of a framework capped at DKK 15 billion over twelve months. The most recent weekly disclosure — filed via a Form 6-K mandatory announcement — covered 1,130,000 B-shares bought for DKK 310,059,558. Following these transactions, the company holds treasury B-shares equivalent to 1.3% of its share capital.
The distinction matters for how the flow is read. These purchases sit inside an existing mandate rather than signalling a newly resolved expansion, and the disclosure announced no cancellation of the repurchased stock. Novo also reported a net outflow of its own shares under remuneration programmes, transfers made outside the buyback and therefore to be assessed separately from it. Continued execution of a capital-return plan tells investors nothing on its own about the direction of the underlying business.
A Paediatric Readout Alongside the Repurchases
On the pipeline side, Novo disclosed results from STEP Young, a Phase III trial testing semaglutide in children aged six to under twelve with obesity. At the 68-week analysis, body-mass index fell by an estimated 17.4% in the treated group, against a 2.2% increase among placebo recipients. Close to 80% of children on semaglutide achieved a BMI reduction of at least 10%; no child in the placebo arm did. Semaglutide remains under clinical investigation for this use.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Danish access to Ozempic also widened. The national medicines regulator granted the 2 mg dose conditional general reimbursement on 9 November, following a confidential price negotiation. Eligibility stays restricted to defined groups of patients with type 2 diabetes.
Guidance Raised, but the Range Still Cuts Both Ways
Alongside its 4 November results, Novo lifted its full-year outlook: revenue and operating profit are each expected to grow between minus 2% and plus 2% at constant currencies. The upgrade is a positive marker, yet the band still spans contraction as well as expansion, so it is not proof of a broad recovery. In the third quarter of 2026, adjusted operating profit rose 27% at constant currencies to DKK 31.7 billion. Within that quarter the mix pulled in opposite directions — obesity revenue climbed 22% while diabetes revenue slipped 5% — and strength in one franchise does not offset weakness in the other.
US List Prices Add a Concrete Variable
From 1 January 2027, US list prices are set to fall by roughly 50% for Wegovy and about 35% for Ozempic. The percentages alone cannot pin down the effect on revenue and earnings, but they give a clear reason not to treat the buyback in isolation as a buying signal. Whether the capital return becomes a convincing valuation argument rests on operational stabilisation and on how the business performs once those US prices take effect.
Ad
Novo Nordisk Stock: New Analysis - 17 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
